Organigram Holdings Inc (OGI)

$1.95

+0.05

(+2.63%)▲

Market is closed - opens 7 PM, 24 Apr 2024

Insights on Organigram Holdings Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 46.04M → 36.45M (in $), with an average decrease of 20.8% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -213.45M → -15.75M (in $), with an average increase of 328.2% per quarter

  • Vs NBIX

    In the last 1 year, Neurocrine Biosciences Inc. has given 28.3% return, outperforming this stock by 33.3%

  • Vs NBIX

    In the last 3 years, Neurocrine Biosciences Inc. has given 38.2% return, outperforming this stock by 120.2%

Performance

  • $1.86
    $1.98
    $1.95
    downward going graph

    4.62%

    Downside

    Day's Volatility :6.06%

    Upside

    1.52%

    downward going graph
  • $0.97
    $2.91
    $1.95
    downward going graph

    50.25%

    Downside

    52 Weeks Volatility :66.66%

    Upside

    32.99%

    downward going graph

Returns

PeriodOrganigram Holdings IncSector (Health Care)Index (Russel 2000)
3 Months
1.06%
-0.4%
0.0%
6 Months
84.47%
9.6%
0.0%
1 Year
-6.86%
3.9%
-1.3%
3 Years
-82.01%
12.8%
-22.1%

Highlights

Market Capitalization
195.2M
Book Value
$3.18
Earnings Per Share (EPS)
-1.82
Wall Street Target Price
8.8
Profit Margin
-153.8%
Operating Margin TTM
-43.7%
Return On Assets TTM
-5.56%
Return On Equity TTM
-54.53%
Revenue TTM
149.2M
Revenue Per Share TTM
1.84
Quarterly Revenue Growth YOY
-14.000000000000002%
Gross Profit TTM
35.1M
EBITDA
-25.4M
Diluted Eps TTM
-1.82
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.32
EPS Estimate Next Year
-0.05
EPS Estimate Current Quarter
-0.09
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    50%Buy
    50%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Organigram Holdings Inc(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
7
8
Hold
6
6
6
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 351.28%

Current $1.95
Target $8.80

Company Financials

FY18Y/Y Change
Revenue
9.5M
↑ 117.53%
Net Income
15.7M
↓ 288.37%
Net Profit Margin
165.04%
↑ 355.63%
FY19Y/Y Change
Revenue
80.4M
↑ 546.98%
Net Income
-9.5M
↓ 146.33%
Net Profit Margin
-11.82%
↓ 176.86%
FY20Y/Y Change
Revenue
66.6M
↑ 7.94%
Net Income
-104.5M
↑ 1332.63%
Net Profit Margin
-156.87%
↓ 145.05%
FY21Y/Y Change
Revenue
62.7M
↓ 8.79%
Net Income
-105.1M
↓ 2.65%
Net Profit Margin
-167.43%
↓ 10.56%
FY22Y/Y Change
Revenue
111.4M
↑ 84.19%
Net Income
-10.9M
↓ 89.22%
Net Profit Margin
-9.8%
↑ 157.63%
FY23Y/Y Change
Revenue
110.4M
↑ 2.33%
Net Income
-169.9M
↑ 1506.66%
Net Profit Margin
-153.8%
↓ 144.0%
Q3 FY22Q/Q Change
Revenue
34.7M
↑ 19.32%
Net Income
-4.7M
↑ 120.45%
Net Profit Margin
-13.51%
↓ 6.2%
Q4 FY22Q/Q Change
Revenue
31.9M
↓ 4.75%
Net Income
3.9M
↓ 186.74%
Net Profit Margin
12.3%
↑ 25.81%
Q1 FY23Q/Q Change
Revenue
29.1M
↓ 8.84%
Net Income
-5.5M
↓ 240.51%
Net Profit Margin
-18.96%
↓ 31.26%
Q2 FY23Q/Q Change
Revenue
24.2M
↓ 16.99%
Net Income
-157.2M
↑ 2750.57%
Net Profit Margin
-651.06%
↓ 632.1%
Q3 FY23Q/Q Change
Revenue
46.0M
↑ 40.43%
Net Income
-33.0M
↓ 84.54%
Net Profit Margin
-71.66%
↑ 579.4%
Q4 FY23Q/Q Change
Revenue
26.9M
↓ 20.82%
Net Income
-11.6M
↓ 52.26%
Net Profit Margin
-43.2%
↑ 28.46%
FY18Y/Y Change
Total Assets
232.0M
↑ 226.01%
Total Liabilities
90.5M
↑ 1106.68%
FY19Y/Y Change
Total Assets
428.5M
↑ 41.63%
Total Liabilities
101.5M
↓ 13.95%
FY20Y/Y Change
Total Assets
320.4M
↓ 2.54%
Total Liabilities
90.6M
↑ 16.33%
FY21Y/Y Change
Total Assets
439.1M
↑ 32.66%
Total Liabilities
58.8M
↓ 37.16%
FY22Y/Y Change
Total Assets
440.9M
↑ 4.17%
Total Liabilities
52.8M
↓ 6.96%
FY23Y/Y Change
Total Assets
220.9M
↓ 48.28%
Total Liabilities
19.9M
↓ 61.14%
Q3 FY22Q/Q Change
Total Assets
440.9M
↓ 1.11%
Total Liabilities
52.8M
↓ 4.37%
Q4 FY22Q/Q Change
Total Assets
422.0M
↓ 0.67%
Total Liabilities
42.7M
↓ 16.03%
Q1 FY23Q/Q Change
Total Assets
406.5M
↓ 3.75%
Total Liabilities
31.4M
↓ 26.46%
Q2 FY23Q/Q Change
Total Assets
256.8M
↓ 36.83%
Total Liabilities
34.3M
↑ 9.12%
Q3 FY23Q/Q Change
Total Assets
298.5M
↓ 14.36%
Total Liabilities
26.8M
↓ 42.33%
Q4 FY23Q/Q Change
Total Assets
220.5M
↑ 0.19%
Total Liabilities
30.4M
↑ 53.51%
FY18Y/Y Change
Operating Cash Flow
-9.7M
↑ 107.88%
Investing Cash Flow
-75.2M
↑ 148.48%
Financing Cash Flow
125.7M
↑ 301.68%
FY19Y/Y Change
Operating Cash Flow
-35.1M
↑ 176.14%
Investing Cash Flow
-46.8M
↓ 52.26%
Financing Cash Flow
74.3M
↓ 54.65%
FY20Y/Y Change
Operating Cash Flow
-34.6M
↑ 28.63%
Investing Cash Flow
-106.0M
↑ 195.4%
Financing Cash Flow
123.0M
↑ 115.75%
FY21Y/Y Change
Operating Cash Flow
-22.7M
↓ 36.64%
Investing Cash Flow
-91.2M
↓ 16.71%
Financing Cash Flow
138.3M
↑ 8.79%
FY22Y/Y Change
Operating Cash Flow
-27.7M
↑ 26.66%
Investing Cash Flow
33.6M
↓ 138.25%
Financing Cash Flow
4.1M
↓ 96.95%
FY23Y/Y Change
Operating Cash Flow
-26.0M
↓ 2.82%
Investing Cash Flow
3.4M
↓ 89.64%
Financing Cash Flow
-604.8K
↓ 115.33%
Q3 FY22Q/Q Change
Operating Cash Flow
-15.0M
↑ 209.09%
Investing Cash Flow
-29.8M
↓ 175.39%
Financing Cash Flow
-123.0K
↓ 39.02%
Q4 FY22Q/Q Change
Operating Cash Flow
2.6M
↓ 117.59%
Investing Cash Flow
-1.3M
↓ 95.62%
Financing Cash Flow
-147.2K
↑ 24.22%
Q1 FY23Q/Q Change
Operating Cash Flow
-14.5M
↓ 668.86%
Investing Cash Flow
-2.5M
↑ 101.17%
Financing Cash Flow
-154.7K
↑ 5.0%
Q2 FY23Q/Q Change
Operating Cash Flow
-4.1M
↓ 72.02%
Investing Cash Flow
-2.5M
↑ 0.0%
Financing Cash Flow
-120.1K
↓ 22.38%

Technicals Summary

Sell

Neutral

Buy

Organigram Holdings Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Organigram Holdings Inc
Organigram Holdings Inc
-24.6%
84.47%
-6.86%
-82.01%
-93.92%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
-4.7%
23.86%
29.07%
38.18%
65.61%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
-0.83%
1.09%
-6.49%
12.82%
12.82%
Zoetis Inc.
Zoetis Inc.
-13.27%
-12.59%
-17.47%
-14.66%
42.73%
Viatris Inc.
Viatris Inc.
-4.9%
26.12%
20.58%
-15.79%
-31.15%
Catalent, Inc.
Catalent, Inc.
-0.62%
32.76%
24.72%
-51.21%
26.1%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Organigram Holdings Inc
Organigram Holdings Inc
NA
NA
NA
-0.32
-0.55
-0.06
NA
3.18
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
53.44
53.44
0.44
4.78
0.13
0.09
NA
22.61
Haleon Plc Spon Ads
Haleon Plc Spon Ads
29.36
29.36
1.69
0.45
0.07
0.04
0.03
1.8
Zoetis Inc.
Zoetis Inc.
28.82
28.82
2.58
5.8
0.5
0.13
0.01
10.9
Viatris Inc.
Viatris Inc.
222.4
222.4
NA
2.78
0.0
0.03
0.04
17.05
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.06
0.48
-0.3
-0.01
NA
20.41
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Organigram Holdings Inc
Organigram Holdings Inc
Buy
$195.2M
-93.92%
NA
-153.8%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$13.3B
65.61%
53.44
13.23%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$37.5B
12.82%
29.36
9.28%
Zoetis Inc.
Zoetis Inc.
Buy
$66.8B
42.73%
28.82
27.43%
Viatris Inc.
Viatris Inc.
Hold
$13.2B
-31.15%
222.4
0.35%
Catalent, Inc.
Catalent, Inc.
Hold
$10.0B
26.1%
211.02
-31.77%

Institutional Holdings

  • Mirae Asset Global Investments (Korea) Co Ltd

    1.24%

  • Renaissance Technologies Corp

    0.55%

  • AXS Investments LLC

    0.51%

  • Bank of Montreal

    0.50%

  • BMO Capital Markets Corp.

    0.50%

  • AdvisorShares Investments, LLC

    0.39%

Company Information

as part of canada’s marihuana for medical purposes regulations (mmpr), organigram (tsx-v:ogi) is atlantic canada's original licensed producer of medical marijuana. we are dedicated to consistently providing our clients with the highest quality, organically grown medicine and service. if you have questions or want to learn more, visit www.organigram.ca or give our client services team a call at 1-855-961-9420.

Organization
Organigram Holdings Inc
Employees
984
CEO
Ms. Beena G. Goldenberg
Industry
Pharmaceuticals: Other

Discover More

FAQs